COVID-19 puts the global supply chains for both pharma and medtech products under pressure. In the US, up to 80% of active pharmaceutical ingredients are sourced globally, with China and India playing critical roles. Industry executives estimate that Asia produces up to 50% of N95 masks (plus raw materials and fabrics for N95 masks manufactured elsewhere) as well as a large majority of isolation gowns.
While many pharma and medtech supply chains have been able to largely meet demand to date from existing inventory, it is critical that companies activate sophisticated analytics and scenario modelling to fully understand their supply chains and identify the top products facing potential supply issues, with a perspective on the next few months, taking into account potential more-aggressive infection scenarios.
You can read the details here.